An Analysis of Predictor Variables for Adjuvant Treatment of Breast Cancer

Published in: Cancer Chemotherapy and Pharmacology, v. 2, no. 3, 1979, p. 147-158

by S Kister, Jerry Aroesty, William H. Rogers, Carolyn R. Huber, K Willis, Peter A. Morrison, G Shangold, Thomas L. Lincoln

Read More

Access further information on this document at www.springerlink.com

This article was published outside of RAND. The full text of the article can be found at the link above.

Modern computer-based statistical analysis of a well-documented data base can facilitate the selection of breast cancer patients for adjuvant chemotherapy. Traditional selection criteria are dominated by the number of positive axillary lymph nodes found by pathologic examination. However, patients of the same nodal status (0+, 13+, 47+, >7+) are still heterogeneous with regard to risk of metastatic recurrence and benefits of adjuvant treatment. A pilot study of 103 patients of similar nodal status (13+) followed for up to 10 years was undertaken to determine whether data already in the patient's record at the time of pathologic examination and derived from the patient's history as well as from clinical, surgical and pathologic examination could supplement nodal status in predicting disease recurrence. Preliminary processing and screening for promising variables were performed with CLINFO; maximum-likelihood procedures were then used to relate the probability of disease recurrence to those variables that appeared to be significant. Parametric models of hazard rate for the individual patient were employed corresponding to both exponential and Wiebull distributions of disease-free interval. The hazard rate was related log-linearly to a set of prognostic variables, and model parameters were determined by fitting to the data. Factors that favor longer disease-free intervals (in quantitative order of importance) are: (1) Nipple involved clinically at presentation; (2) Lesion had soft or rubbery consistency on palpation; (3) Disease discovered by physician; (4) Homolateral lymph nodes not involved clinically; (5) Margin from tumor to fascia >1 cm; (6) No maternal history of breast cancer; (7) Increasing age of patient; (8) Presence of specialized histology. Based on the findings of this pilot study, a quantitative summary of personal (SK) and institutional experience is developed in which the probability of recurrence for the individual patient and the associated confidence intervals are used to classify patients with regard to risk of recurrence.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/research-integrity.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.